topotecan has been researched along with Retroperitoneal Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, JR; Arndt, CA; Donaldson, SS; Hawkins, DS; Lyden, ER; Morris, CD; Rodeberg, DA; Wolden, SL | 1 |
| Kurzrock, R; Subbiah, V; Trent, JC | 1 |
| Bajorin, DF; Bosl, GJ; Carousso, M; Feldman, DR; Ginsberg, MS; Motzer, RJ; Patil, S; Sheinfeld, J; Trinos, MJ | 1 |
1 trial(s) available for topotecan and Retroperitoneal Neoplasms
| Article | Year |
|---|---|
Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Disease Progression; Disease-Free Survival; Female; Humans; Infant; Lymph Nodes; Male; Meningeal Neoplasms; Radiotherapy Dosage; Retroperitoneal Neoplasms; Rhabdomyosarcoma, Alveolar; Rhabdomyosarcoma, Embryonal; Topotecan; Treatment Failure; Tumor Burden; Vincristine | 2015 |
2 other study(ies) available for topotecan and Retroperitoneal Neoplasms
| Article | Year |
|---|---|
Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; Middle Aged; Perivascular Epithelioid Cell Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Retroperitoneal Neoplasms; Sirolimus; Topotecan; TOR Serine-Threonine Kinases; Treatment Failure | 2010 |
Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design.
Topics: Adolescent; Adult; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Endpoint Determination; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Germ Cell and Embryonal; Pyrroles; Retroperitoneal Neoplasms; Retrospective Studies; Sunitinib; Suramin; Testicular Neoplasms; Topotecan; Treatment Outcome; Young Adult | 2012 |